XML 25 R5.htm IDEA: XBRL DOCUMENT v2.3.0.15
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands
9 Months Ended184 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Cash flows from operating activities:   
Net loss$ (11,585)$ (12,849)$ (249,891)
Adjustments to reconcile net loss to net cash used in operating activities:   
Accretion of interest on notes payable, net of amortization of debt premium  100
Amortization of investment premiums, net  (2,297)
Change in valuation of derivative  308
Change in valuation of warrants(643)443(6,713)
Warrant re-pricing  44
Depreciation and amortization25035112,564
Amortization of intangible assets  886
Fixed asset impairment  221
Goodwill and intangibles impairment  7,934
Unrealized foreign exchange loss(29) 7,718
Deferred revenue  (98)
Compensation for warrants issued to non-employees  1,215
Shares issued for IP rights  446
(Gain) loss on disposal of property, plant and equipment (12)99
Stock based compensation6771,39018,818
Provision for restructuring  1,779
Amortization of issuance costs of Preferred Ordinary "C" shares  2,517
Changes in operating assets and liabilities:   
Prepaid expenses, inventory and other current assets450675218
Accounts payable, accrued liabilities and other current liabilities162(2,300)(5,728)
Net cash used in operating activities(10,718)(12,302)(209,860)
Investing activities:   
Purchase of ALIGN  (3,763)
Purchase of property, plant and equipment(6)(8)(8,837)
Proceeds from sale of property, plant and equipment 35158
Purchase of short-term investments  (156,657)
Redemptions of short-term investments, net of maturities  162,729
Net cash provided by (used in) investing activities(6)27(6,370)
Financing activities:   
Payment of capital lease obligations  (3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs  121,678
Proceeds from issuance of common stock and warrants, net of issuance costs9,25816,57291,662
Net proceeds from stock options and warrants exercised32,710173
Payment of preferred stock dividend(364) (1,898)
Repayment of government loan  (455)
Government loan received  414
Loan received from Cyclacel Group Plc  9,103
Proceeds of committable loan notes issued from shareholders  8,883
Loans received from shareholders  1,645
Cash and cash equivalents assumed on stock purchase  17,915
Costs associated with stock purchase  (1,951)
Net cash provided by financing activities8,89719,282243,450
Effect of exchange rate changes on cash and cash equivalents7(18)455
Net increase (decrease) in cash and cash equivalents(1,820)6,98927,675
Cash and cash equivalents at beginning of period29,49511,493 
Cash and cash equivalents at end of period27,67518,48227,675
Cash received during the period for:   
Interest201411,735
Taxes6881,06718,210
Cash paid during the period for:   
Interest (155)(1,914)
Schedule of non-cash transactions:   
Acquisitions of equipment purchased through capital leases  3,470
Issuance of common shares in connection with license agreements  592
Issuance of ordinary shares on conversion of bridging loan  1,638
Issuance of preferred Ordinary "C" shares on conversion of secured convertible loan notes and accrued interest  8,893
Issuance of ordinary shares in lieu of cash bonus  164
Issuance of other long term payable on ALIGN acquisition  $ 1,122